AFT Pharmaceuticals has suffered another blow over its Maxigesic advertisements, with a judge finding the marketing material misled consumers by claiming to provide better, faster and more effective pain relief than paracetamol or ibuprofen.
Generic drug maker Sandoz has successfully appealed a $26.3 million judgment finding it infringed a patent owned by rival H Lundbeck relating to the top-selling antidepressant Lexapro.
AFT Pharmaceuticals is seeking to reopen a lawsuit against Reckitt Benckiser over ads for its painkiller Maxigesic after judgment was delivered in the matter, claiming the judge’s declarations contained an error, an argument slammed by Reckitt as “extraordinary”.
A software company is suing a subsidiary of AMP for breach of contract after the financial services firm allegedly induced 11 employees to jump ship after licensing its online advisor platform.
AFT Pharmaceuticals has lost its challenge to a ruling that ads claiming its painkiller Maxigesic is more effective than Nuremol were misleading and deceptive, with the Full Federal Court saying the primary judge did not err in finding the ads lacked an adequate scientific basis.
International hip-hop superstar Jay-Z has sued an Australian children’s book manufacturer for “flagrant, glaring and contumelious” intellectual property infringement with its ‘AB to Jay-Z’ baby books.
AFT Pharmaceuticals has challenged a Federal Court decision that found its Maxisegic ads were misleading and deceptive, saying the judge “set the bar too high” by requiring it to prove there was an adequate scientific foundation for its painkiller representations.
Israeli drug giant Teva and German drug maker Boehringer Ingelheim have settled their dispute over a patented capsule used to deliver the medicine in Boehringer’s top-selling inhaler Spiriva.
Mylan has renewed calls for a temporary injunction against Sun Pharma pending an appeal of a ruling invalidating its patents for Lipidil, and has sued a second generic drug maker, Cipla, over the cholesterol-lowering medication.
German pharmaceutical company Boehringer has struck back at a patent lawsuit brought by Teva, filing a cross-claim alleging Teva is threatening to infringe three of its patents related to its blockbuster inhaler Spiriva with the planned launch of a competing inhaler in Australia.